Nyxoah SA
Develops hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA).
NYXH | BR
Overview
Corporate Details
- ISIN(s):
- BE0974358906
- LEI:
- 5493002O1ESKZ18OXR80
- Country:
- Belgium
- Address:
- Rue Edouard Belin 12, 1435 Mont-Saint-Guibert
- Website:
- https://www.nyxoah.com/
- Sector:
- Manufacturing
Description
Nyxoah SA is a medical technology company focused on the development and commercialization of solutions for Obstructive Sleep Apnea (OSA). The company's lead product is the Genio® system, a hypoglossal neurostimulation (HNS) therapy designed for patients with moderate to severe OSA. The system features a patient-centered, leadless, and battery-free implantable stimulator. It functions by providing bilateral stimulation to the hypoglossal nerve, which controls tongue muscles, to maintain an open airway during sleep.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-24 21:30 |
PR FY 2021 earnings (FR).pdf
|
French | 248.2 KB | ||
| 2022-02-11 22:30 |
2022 02 11 - Press release - Number of shares (ENG) (final).pdf
|
English | 153.9 KB | ||
| 2022-02-11 22:30 |
2022 02 11 - Press release - Number of shares (FR) (final).pdf
|
French | 152.7 KB | ||
| 2021-11-26 22:30 |
2021 11 26 - Press release - Number of shares (ENG) (final).pdf
|
English | 154.2 KB | ||
| 2021-11-26 22:30 |
2021 11 26 - Press release - Number of shares (FR) (final).pdf
|
French | 152.6 KB | ||
| 2021-10-29 22:30 |
2021 10 29 - Press release - Number of shares (ENG) (final).pdf
|
English | 154.9 KB | ||
| 2021-10-29 22:30 |
2021 10 29 - Press release - Number of shares (FR) (final).pdf
|
French | 153.8 KB | ||
| 2021-10-04 22:30 |
Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Colla…
|
English | 109.6 KB | ||
| 2021-10-04 22:30 |
Nyxoah Annonce l’Approbation Marquage CE pour l’Indication de Traitement des Pa…
|
French | 91.1 KB | ||
| 2021-10-01 22:30 |
2021 10 01 - Press release - Number of shares (ENG) (final).pdf
|
English | 154.4 KB | ||
| 2021-10-01 22:30 |
2021 10 01 - Press release - Number of shares (FR) (final).pdf
|
French | 153.2 KB | ||
| 2021-09-14 08:00 |
Nyxoah Announces U.S. FDA Breakthrough Device Designation
|
English | 92.8 KB | ||
| 2021-09-14 08:00 |
Nyxoah Annonce l’Obtention de la Désignation « Breakthrough Device » de la FDA
|
French | 93.4 KB | ||
| 2021-09-12 22:30 |
2021 09 12 - Press release - Number of shares (ENG) (final).pdf
|
English | 154.7 KB | ||
| 2021-09-12 22:30 |
2021 09 12 - Press release - Number of shares (FR) (final).pdf
|
French | 153.4 KB |
Automate Your Workflow. Get a real-time feed of all Nyxoah SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nyxoah SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nyxoah SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-19 | Laurette Renard | Close relation | Sell | 5,000 | 39,000.00 EUR |
| 2024-09-05 | Hambrecht Jürgen | Board | Sell | 980,000 | 6,840,400.00 EUR |
| 2024-09-05 | JH Capital GmbH | Close relation | Buy | 980,000 | 6,840,400.00 EUR |
| 2024-01-25 | Tompkins Patrick | Executive member | Buy | 2,000 | 18,020.00 USD |
| 2023-12-28 | Onkelinx Bruno | Executive member | Buy | 470 | 2,035.10 EUR |
| 2023-08-18 | Moreau Loïc | Executive member | Buy | 6,427 | 48,416.52 EUR |
| 2023-08-14 | Moreau Loïc | Executive member | Buy | 3,800 | 28,697.60 EUR |
| 2023-08-11 | Moreau Loïc | Executive member | Buy | 3,000 | 21,957.60 EUR |
| 2023-07-04 | Wildman Ventures LLC | Board | Buy | 25,000 | N/A |
| 2023-07-02 | Gianello Pierre | Board | Buy | 25,000 | N/A |
Peer Companies
